Alliance Pharma PLC AGM Statement (2950O)
May 27 2015 - 02:01AM
UK Regulatory
TIDMAPH
RNS Number : 2950O
Alliance Pharma PLC
27 May 2015
For immediate release 27 May 2015
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
AGM Statement
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical
company, will hold its Annual General Meeting ("AGM") in London
later this morning. At the meeting, the Company's Chairman, Andrew
Smith, will make the following statement:
"Trading in the first four months of 2015 has been satisfactory
with revenue of GBP15.6 million, which is 6% higher than the same
period last year (2014: GBP14.7 million).
"Hydromol(TM), our biggest brand, has continued to grow
strongly, with sales in the first four months of the year up 14% on
the same period in the prior year. In the first three months after
acquisition, MacuShield(TM) sales have been in line with our
expectations, up 12% on the same period the previous year.
"We continue to expect supplies of ImmuCyst(TM) to be resumed in
the second half of the year, though initial quantities are still
uncertain.
"As previously announced, Richard Wright will be stepping down
as Finance Director on 31 May 2015. On behalf of the Board, I
extend our thanks to Richard for his excellent work at Alliance and
wish him every success in the future. The process to recruit his
replacement is progressing well.
"We have a strong pipeline of potential acquisition
opportunities and have more than GBP20 million of undrawn bank
facilities available to us.
"We look forward to the remainder of 2015 with confidence."
For further information:
Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Richard Wright, Finance Director
www.alliancepharma.co.uk
+ 44 (0) 20 7466
Buchanan 5000
Mark Court / Sophie Cowles
/ Jane Glover
+ 44 (0) 20 7260
Numis Securities Limited 1000
Nominated Adviser: Michael
Meade / Freddie Barnfield
Corporate Broking: David
Poutney
Notes to editors:
About Alliance
Alliance, founded in 1998, is an AIM listed speciality
pharmaceutical company based in Chippenham, Wiltshire, UK. The
Company has a strong track record of acquiring the rights to
established niche products and owns or licenses the rights to more
than 60 pharmaceutical products and continues to explore
opportunities to expand the range.
Alliance joined the AIM market of the London Stock Exchange in
December 2003 and trades under the symbol APH.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGMPKADPKBKBDPB
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Feb 2024 to Mar 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2023 to Mar 2024